TAK Biopharma IVS: Financial statements 2019
CVR: 37962872
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
TAK Biopharma IVS (CVR 37962872) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 379,951 and a net result of DKK -22,190 compared with DKK 149,224 the year before. That is an increase of 84.9% compared with the year before. The profit margin was -5.8%. Equity in the 2019 report amounted to DKK -59,720.
- Revenue
- DKK 379,951
- Gross Profit
- DKK 299,990
- Profit/Loss
- DKK -22,190
- Equity
- DKK -59,720
- Total Assets
- DKK 70,309
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 380K | 300K | -22K | -60K | - |
| 2018 | 206K | 149K | 149K | -38K | - |
| 2017 | 80K | 67K | -23K | -187K | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
TAK Biopharma IVS has published its annual report for 2018. Revenue came to DKK 205,532, and the net result was DKK 149,224.
About TAK Biopharma IVS
TAK Biopharma IVS was a Danish company of the type Iværksætterselskab based in København N, founded in 2016. The company has been dissolved on 20 June 2021. The company was registered under the industry Fremstilling af farmaceutiske råvarer. The company has 1 employee (2020). In 2019, the company reported revenue of DKK 379,951 and a net result of DKK -22,190 compared with DKK 149,224 the year before. Equity in the 2019 report amounted to DKK -59,720.
